17.42
1.69%
-0.30
アフターアワーズ:
17.507
0.087
+0.50%
TG Therapeutics Inc (TGTX) 最新ニュース
TG Therapeutics (TGTX) Stock Moves -0.6%: What You Should Know - Yahoo Singapore News
Yahoo Singapore News
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab ... - br.ADVFN.com
br.ADVFN.com
(TGTX) Trading Report - Stock Traders Daily
Stock Traders Daily
U.S. FDA approves TG Therapeutics' multiple sclerosis drug; shares surge - Yahoo Movies Canada
Yahoo Movies Canada
AMC Entertainment, TG Therapeutics and Interesting findings in the market, within your browser - FOREX.com
FOREX.com
Wall Street Breakfast: The Week Ahead
Seeking Alpha
TG Therapeutics (TGTX) Withdraws FDA Submission, Stock Down - Yahoo Canada Shine On
Yahoo Canada Shine On
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Defense World
TG Therapeutics (TGTX) Stock Moves -0.6%: What You Should Know - Yahoo Singapore News
Yahoo Singapore News
FY2025 Earnings Estimate for TG Therapeutics, Inc. (NASDAQ:TGTX) Issued By HC Wainwright - MarketBeat
MarketBeat
Q2 2024 Earnings Forecast for TG Therapeutics, Inc. Issued By B. Riley (NASDAQ:TGTX) - Defense World
Defense World
TG Therapeutics, Inc. to Post FY2025 Earnings of $0.11 Per Share, HC Wainwright Forecasts (NASDAQ:TGTX) - Defense World
Defense World
FY2025 Earnings Estimate for TG Therapeutics, Inc. (NASDAQ:TGTX) Issued By HC Wainwright - MarketBeat
MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) to Post FY2025 Earnings of $0.72 Per Share, B. Riley Forecasts - Defense World
Defense World
TG Therapeutics, Inc. (NASDAQ:TGTX) to Post FY2025 Earnings of $0.72 Per Share, B. Riley Forecasts - MarketBeat
MarketBeat
Earnings call: TG Therapeutics sees strong Q1 growth with Briumvi - Investing.com
Investing.com
TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts - Simply Wall St
Simply Wall St
Why TG Therapeutics Stock Was Rocketing Higher This Week - MSN
MSN
Why TG Therapeutics Stock Was Rocketing Higher This Week
The Motley Fool
TG Therapeutics, Inc. (NASDAQ:TGTX) to Post FY2025 Earnings of $0.72 Per Share, B. Riley Forecasts - MarketBeat
MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasted to Post Q2 2024 Earnings of ($0.05) Per Share - Defense World
Defense World
B. Riley Research Analysts Increase Earnings Estimates for TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
MarketBeat
TG Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Yahoo Finance
TG Therapeutics: Q1 Earnings Snapshot - Milford Mirror
Milford Mirror
TG Therapeutics (NASDAQ:TGTX) Shares Gap Up to $13.66 - MarketBeat
MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Expected to Post FY2026 Earnings of $1.60 Per Share - MarketBeat
MarketBeat
TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX) - MarketBeat
MarketBeat
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
GlobeNewswire Inc.
After Plunging -9.82% in 4 Weeks, Here's Why the Trend Might Reverse for TG Therapeutics (TGTX)
Zacks Investment Research
17500 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Bought by Strs Ohio - Defense World
Defense World
After Plunging -9.82% in 4 Weeks, Here's Why the Trend Might Reverse for TG Therapeutics (TGTX) - Yahoo Canada Finance
Yahoo Canada Finance
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
GlobeNewswire Inc.
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
GlobeNewswire Inc.
TG Therapeutics wins VA contract for MS drug - Investing.com Nigeria
Investing.com Nigeria
TG Therapeutics: The Cloud Over Briumvi (NASDAQ:TGTX) - Seeking Alpha
Seeking Alpha
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
GlobeNewswire Inc.
TG Therapeutics highlights BRIUMVI data at AAN meeting - Investing.com
Investing.com
TG Therapeutics Breaks Below 200-Day Moving Average - Notable for TGTX - Nasdaq
Nasdaq
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Zacks Investment Research
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet - Simply Wall St
Simply Wall St
Is TG Therapeutics, Inc.'s (NASDAQ:TGTX) Recent Price Movement Underpinned By Its Weak Fundamentals? - Yahoo Finance
Yahoo Finance
Director Laurence Charney Sells 22000 Shares of TG Therapeutics Inc (TGTX) - GuruFocus.com
GuruFocus.com
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
GlobeNewswire Inc.
Rare Stock Picks In February 2024 - From 32 Discerning Analysts
Seeking Alpha
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
GlobeNewswire Inc.
Earnings call: TG Therapeutics reports robust BRIUMVI sales in 2023 - Investing.com
Investing.com
Company News for Feb 29, 2024
Zacks Investment Research
大文字化:
|
ボリューム (24 時間):